Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.
Advertisement

Related Content

NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
Singapore S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara
Vioxx Cardiovascular Safety Questioned In Original NDA, Review Docs Show

Topics

Advertisement
UsernamePublicRestriction

Register

PS004779

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel